Incidence of Tuberculosis Disease and Latent Tuberculosis Infection in Patients with End Stage Renal Disease in an Endemic Region

Basit Öğe Kaydı
dc.contributor.authorAtes, Gungor
dc.contributor.authorYildiz, Tekin
dc.contributor.authorDanis, Ramazan
dc.contributor.authorAkyildiz, Levent
dc.contributor.authorErturk, Baykal
dc.contributor.authorBeyazit, Huseyin
dc.contributor.authorTopcu, Fusun
dc.date.accessioned2024-04-24T17:20:27Z
dc.date.available2024-04-24T17:20:27Z
dc.date.issued2010
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim. Patients in chronic renal failure suffer impaired cellular immunity and have an increased risk of tuberculosis (TB). Our aim in this multicenter study was to determine the incidence of TB and to evaluate latent tuberculosis infection (LTBI) in hemodialysis patients. Methods. We retrospectively evaluated the frequency of TB in 779 dialysis patients at 13 hemodialysis centers in five different cities in Southeast Turkey. The tuberculin skin test (TST) was conducted in 733 patients to detect LTBI. Results. The mean age of the patients was 51.2 +/- 15.9 years; 398 (51.1%) of the patients were female, and 53.9% of patients had a BCG scar. The mean dialysis duration time was 35.1 +/- 33.4 months. TB was diagnosed in 34 cases. The incidence rate of TB in patients undergoing hemodialysis was 3.1%. Ten patients had a history of TB before beginning hemodialysis, and 24 patients had a history of TB after beginning hemodialysis. A diagnosis of TB was made based on clinical data in eight patients and microbiologically or pathologically in 26 patients. The median time between the initiation of dialysis to the diagnosis of TB was 11 months. Extrapulmonary TB occurred in 45.8% of cases, and the most common site of involvement was the lymph nodes. The TST was positive in 61.8% of TB patients and in 37.5% of those with no history of TB. Conclusions. The incidence of TB is high in hemodialysis patients, and they should be evaluated periodically to exclude insidious infection and reduce morbidity and mortality.en_US
dc.identifier.doi10.3109/08860220903367528
dc.identifier.endpage95en_US
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue1en_US
dc.identifier.pmid20113273
dc.identifier.scopus2-s2.0-76449088151
dc.identifier.scopusqualityQ2
dc.identifier.startpage91en_US
dc.identifier.urihttps://doi.org/10.3109/08860220903367528
dc.identifier.urihttps://hdl.handle.net/11468/19062
dc.identifier.volume32en_US
dc.identifier.wosWOS:000277745400016
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHemodialysisen_US
dc.subjectLatent Tuberculosisen_US
dc.subjectRenal Diseaseen_US
dc.subjectTuberculin Skin Testen_US
dc.subjectTuberculosisen_US
dc.titleIncidence of Tuberculosis Disease and Latent Tuberculosis Infection in Patients with End Stage Renal Disease in an Endemic Regionen_US
dc.titleIncidence of Tuberculosis Disease and Latent Tuberculosis Infection in Patients with End Stage Renal Disease in an Endemic Region
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu